Clinical Trials

SELECTED REPURPOSED DRUGS IN CLINICAL DEVELOPMENT TO TREAT COVID-19

DRUG OR COCKTAIL

ORIGINATOR COMPANY

STATUS AND MECHANISMS

CLINICAL TRIALS (TRIAL POSTING DATE)

DRUG OR COCKTAIL: ASC09/RITONAVIR, LOPINAVIR/RITONAVIR, WITH OR WITHOUT UMIFENOVIR

ORIGINATOR COMPANY: ASCLETIS, ABBVIE, PHARMSTANDARD

STATUS AND MECHANISMS: ASC09 IS AN EXPERIMENTAL HIV-1 PROTEASE INHIBITOR; RITONAVIR AND LOPINAVIR/RITONAVIR ARE APPROVED PROTEASE INHIBITORS FOR HIV/AIDS; UMIFENOVIR IS AN APPROVED ENTRY INHIBITOR AGAINST INFLUENZA

CLINICAL TRIALS (TRIAL POSTING DATE): AT LEAST THREE TRIALS (E.G., CHICTR2000029603, 2/6/20)

DRUG OR COCKTAIL: ASC09/OSELTAMIVIR, RITONAVIR/OSELTAMIVIR, OSELTAMIVIR

ORIGINATOR COMPANY: ASCLETIS, GILEAD, ABBVIE

STATUS AND MECHANISMS: SEE ABOVE; OSELTAMIVIR IS A SIALIDASE INHIBITOR APPROVED FOR INFLUENZA

CLINICAL TRIALS (TRIAL POSTING DATE): ONE TRIAL (NCT04261270, 2/7/20)

AZVUDINE

ZHENGZHOU GRANLEN PHARMATECH

EXPERIMENTAL REVERSE TRANSCRIPTASE INHIBITOR DRUG AGAINST HIV-1/AIDS

ONE TRIAL (CHICTR2000029853, 2/15/20)

VARIOUS COMBINATIONS OF BALOXAVIR MARBOXIL/FAVIPIRAVIR AND LOPINAVIR/RITONAVIR

SHIONOGI, TOYAMA CHEMICAL

BALOXAVIR MARBOXIL IS A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND FAVIPIRAVIR IS A GUANINE ANALOG RNA-DEPENDENT RNA POLYMERASE INHIBITOR APPROVED FOR INFLUENZA A AND B; SEE ABOVE

TWO TRIALS (CHICTR2000029544, 2/3/20; CHICTR2000029548, 2/4/20)

VARIOUS COMBINATIONS OF DARUNAVIR/COBICISTAT ALONE OR WITH LOPINAVIR/RITONAVIR AND THYMOSIN Α1

JANSSEN, GILEAD

DARUNAVIR AND COBICISTAT ARE, RESPECTIVELY, AN HIV-1 PROTEASE INHIBITOR AND INHIBITOR OF CYTOCHROME P450 (CYP)3A ENZYME, APPROVED AS A COMBINATION AGAINST HIV-1/AIDS. THYMOSIN Α1 IS AN IMMUNE RESPONSE BOOSTING AGENT

TWO TRIALS (NCT04252274, 2/5/20; CHICTR2000029541, 2/3/20)

REMDESIVIR

GILEAD

PHOSPHORAMIDATE PRODRUG OF AN ADENINE ANALOG USED FOR EBOLA AND MARBURG VIRUS OUTBREAKS (SIMILAR STRUCTURE TO APPROVED HIV REVERSE TRANSCRIPTASE INHIBITORS)

TWO TRIALS (NCT04252664, 2/5/20; NCT04257656, 2/6/20)

CHLOROQUINE OR HYDROXYCHLOROQUINE

SHANGHAI ZHONGXI PHARMACEUTICAL, SHANGHAI ZIYUAN PHARMACEUTICAL, WUHAN WUYAO PHARMACEUTICAL

ENDOSOMAL ACIDIFICATION FUSION INHIBITOR

AT LEAST TEN TRIALS (E.G., CHICTR2000029826, 2/2/20; NCT04261517, 2/14/20)

METHYLPREDNISOLONE

GENERIC

SYNTHETIC CORTICOSTEROID THAT BINDS TO NUCLEAR RECEPTORS TO DAMPEN PROINFLAMMATORY CYTOKINES

ONE TRIAL (NCT04263402, 2/10/20)

INTERFERON ALFA-2B ALONE OR IN COMBINATION WITH LOPINAVIR/RITONAVIR AND RIBAVIRIN

BIOGEN, MERCK

INTERFERON ALFA-2B IS A RECOMBINANT CYTOKINE WITH ANTIVIRAL PROPERTIES; RIBAVIRIN IS A GUANINE DERIVATIVE; AS ABOVE

TWO TRIALS (NCT04254874, 2/5/20; CHICTR2000029308, 1/23/20)

CAMRELIZUMAB AND THYMOSIN

INCYTE, SHANGHAI HENGRUI PHARMACEUTICAL

CAMRELIZUMAB IS A HUMANIZED MONOCLONAL ANTIBODY (MAB) TARGETING PD-1

TWO TRIALS (CHICTR2000029806, 2/14/20; NCT04268537, 2/14/20)

TOCILIZUMAB

CHUGAI PHARMACEUTICAL, ZHEJIANG HISUN PHARMACEUTICAL, JIANGSU QYUN BIO-PHARMACEUTICAL

HUMANIZED MAB TARGETING INTERLEUKIN-6

ONE TRIAL (CHICTR2000029765, 2/13/20)

LAST SEARCH RUN ON 15 FEBRUARY USING HTTPS://CLINICALTRIALS.GOV AND HTTP://WWW.CHICTR.ORG.CN. EXCLUDES TRADITIONAL CHINESE MEDICINES AND BLOOD-DERIVED PRODUCTS, SUCH AS SERUM FROM RECOVERED PATIENTS AND STEM CELLS. ALL TRIALS ARE BEING CONDUCTED IN CHINA.